The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Health innovations are viewed more positively than food and agricultural technologies
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Subscribe To Our Newsletter & Stay Updated
